Compare GSK plc (GSK) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

SOXS, the Direxion Daily Semiconductor Bear 3X Shares ETF, surged 23.58% to $52.52 amid a semiconductor sector pullback, with technical indicators showing a bullish moving average signal but overbought oscillators. The ETF executed a 1:10 stock split on July 15, 2026, and paid a $0.04 dividend in June. Recent news highlights its inverse leverage to chip stocks, with gains driven by declines in memory companies like Micron due to competitive pressures.

Outlook remains volatile as SOXS benefits from semiconductor downturns, but its leveraged structure amplifies risks during sector rallies. Key risks include sustained AI-driven chip strength and high volatility. Analysts caution against shorting semiconductors amid fundamental support for the bullish trend, making SOXS suitable only for tactical bearish bets.